Ascendiant Capital Starts Cytori Therapeutics, Inc. (CYTX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow set for lower open after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil heads for weekly gain as US-Iran fighting resumes; diesel hits record high
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Cytori Therapeutics (CYTX) Reports In-Line Q1 Loss of 7c/Share
May 11, 2015 4:23 PM EDTCytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $2.44 million.
For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.
... More